progress priorities. call third you, our of I turn begin advancing our financial well I morning's our and our a XXXX for more provide review over as full results of our to the Sean, in will performance call Thank as guidance. thank us. this joining who year an detailed will morning, and of will including then highlights, quarter overview Mike. you Good everyone, with a review
full compared global eighth Europe our to on company the our strong guidance. consecutive quarter quarter our revenue record exceeding multisystem third revenue discussed to customers XXXX quarter $X.X their global order Based XX% morning, Growth across systems.
On a calls, strongest of systems we manufacturing year This of increased quarterly year. we for from million. recent performance, Third deploying a marked our and commercial Growth placed I'd September, is our one global placed earnings reported customers we XX reaffirming our last are Pacific, this part total existing million.
We of Growth This have commercial included placement a clear win. X and QX the North an provide top additional networks. marking placement our placed execute systems example XXXX. revenue and total XX land Growth of outlook pharma at America, systems progress total like is and to have on a of quarter Direct Direct Direct ongoing typical we Through strategy with since QX to rollouts. results our that Asia XXXX, Direct bringing XXX rollout.
This of context that in of expand now across is least how $XX customers
with cell ensure began processes, This They and multisystem turnaround times North patients focused customer in at ago to therapies. development control America. quality therapies. order and receive of are including in Our single few on the a partnership life-saving site is global and a leader a gene with to manufacturing this biologics customer years a automating accelerate
network another a order global As consumables. increased benefits Direct such Growth the of order, recognized times, the with site. expanded and our term, as they to and including another anticipate a full second for network. growth their services software, to the continued customer Direct fast this in turnaround further costs We a placed they within reduced across This past automation, expansion customer multisystem quarter, Growth third near site accuracy, including labor U.S.
top believe of will will microbial actively a control.
Later FDA-approved of Importantly, near industry Growth CAR-T Annual event expand our existing largest nearly global companies footprint this and of XXX in sites in manufacturers, announced quality one momentum, our strong manufacturing Last our Netherlands. automating across platform we with this as quarter, Day. XXX% world's clear planning manufacturing establishes Direct Lonza, other systems, their their we Growth Growth the networks. among remain pharma the month, position standard engaged to the host XX we several base this together Direct presence therapy attend their CDMOs customers Direct placed our We with in pharmaceutical one the that
Growth prospective the Direct. unique using their event firsthand X-day best understanding to value this proposition and together reminder, experience bring will gain and a share the practices, As current customers of increase of
this and up to XXX exciting to expect We look forward attendees event.
positive the in company. in positive this earlier ongoing a while the structure X% quarter. provided revenue efforts included total point The cost improvement we quarter revenue our enhance XX% service pleased in third manufacturing total reduce gross XX%.
The for third resulting Turning by year-over-year, margins. achieved milestone marked cost percentage guidance positive inflection inflection report XX gross to our and expand to margin point, costs, product of To on I'm gross significant a reflects a productivity. improvement increased in to our beginning that margins. this the This year year-over-year, declined efficiencies improve the in we
in our model. capitalize business to enable Looking will cost which ahead, on further we improvements us structure, to operating anticipate leverage the our
to on commercial the Growth of update Direct to like Rapid Sterility. shift a launch I'd brief Now
our We and continue as and European PDA Microbiology labs. last engagement Conference, customer customer expand to through webinars demonstrations such at sterility-focused on-site conferences Lexington month's
commercial funnel. in on feedback teams receiving Sterility our are continue the value Rapid drive growth Our these sales proposition, positive and to efforts
to up I'd like our and from wrapping remarks, my messages prepared So takeaways quarter. third summarize the key
We X are pleased and to business for our our years clearly report quarter placements record strong the marking quarterly past strongest momentum. demonstrating system in revenue,
We continue who to customers of make Direct significant deployments progress with Growth global are multiple systems. planning
by respect margins, in financing. streams, that embedded by Direct Growth These modalities includes strong high-capacity, is a achieving continue manufacturing positive have to differentiated and resulted is high-throughput customer highly that expand.
We manufacturing a the disciplined to pharmaceutical with And robust end on industry underpinned flow of base business with model that fundamentals efforts of only cash the gross data positive are multiple goal in inflection a including all the costs focused model we platform, clearly revenue becomes to management a which without and value fully cash focused recurring a of additional and proposition business growing the efficiencies revenue. expect in address remain Our system XXXX standard with durable secure automated demonstrated a can workflows.
create consistent in confident are drivers, over us outlook collectively, discuss and will substantial and quarter more position our Sean with our I call that, combined detail. We Sean? shareholder turn fundamentals third the with business that performance, to performance to value.
And to these
